vbivaccines.com (VBIV) - Gross Profit Rate

Official company branding of VBI Vaccines Inc. (VBIV)

VBI Vaccines Inc. leads the development of hepatitis B treatments through its innovative eVLP platform that mimics viruses. The gross profit margin history illustrates production efficiency, where the 0.00 mark indicates the current status. Previously, the company accelerated the licensing of its developments through strategic alliances with medical organizations. Currently, the business is undergoing bankruptcy proceedings, selling off patents under court supervision.

VBIV: VBI Vaccines Gross Margin 07/04/2022 - 08/17/2024

Financial and market metric breakdowns for VBI Vaccines Inc (VBIV)

- current quotes and average value forecast:
- cash balance and cash flow data:
Fundamental valuation:VBIV - vbivaccines.com
Core merchandise of VBI Vaccines, Inc.

The specifics of VBI Vaccines Inc. (VBIV) biopharmaceuticals are driven by strict FDA control over manufacturing processes and biomaterial disposal. By analyzing the gross profit margin, an investor assesses the efficiency of covering direct drug development costs. This metric determines the viability of the model through the spread between the selling price and the cost of goods sold, allowing for the projection of the business's long-term resilience to cost inflation.